Washington DC Office
1101 Pennsylvania Ave.
Suite 600
Washington DC 20004
Telephone: 202-756-2972


Fort Lauderdale Office
110 E. Broward Blvd.
Suite 1700

Fort Lauderdale, FL 33301
Telephone: 954-315-3934
Facsimile: 954-315-3914

Miami Office
1111 Brickwell Avenue
11th Floor
Miami, FL 33131
Telephone: 305-913-7199

Celebrex News

 

Judge denies class in Fosamax cases against Merck

-Reuters


01/04/2008- A U.S. federal judge has denied motions to certify classes of users of osteoporosis drug Fosamax who wanted Merck & Co to set up a program to monitor them for an ailment involving jaw bone decay.

U.S. District Judge John Keenan in a ruling dated Thursday denied motions to approve classes of current and former users of the popular drug in Pennsylvania, Florida and Louisiana who have not been diagnosed with the ailment.

"The court finds that class-treatment of these claims is inappropriate because they present too many individual questions of fact particular to each class member's claim," Keenan wrote in a 41-page ruling.

More than 360 federal product liability cases have been filed against Merck by people who claim to have taken Fosamax, according to the ruling.

They allege that Fosamax caused the plaintiffs to either develop the ailment, known as osteonecrosis of the jaw, or to suffer an increased risk of developing the condition in the future, Keenan wrote.

Plaintiffs' lawyer Timothy O'Brien said funding the program in the three states would have cost Merck hundreds of millions of dollars. But he added that he expected Merck's liability on the personal injury cases would exceed that.

O'Brien, of law firm Levin Papantonio, estimated that the number of cases in federal and state courts would increase to 1,500 to 2,000 by the end of the year from roughly 460 now.

The first federal cases are expected to go to trial at the end of the year, O'Brien said.

Merck's lawyer, Paul Strain, said the company is defending the lawsuits vigorously.

"We believe that there is no scientific evidence establishing that Fosamax causes this condition," Strain said. "We believe we have meritorious defenses."

Merck expects Fosamax sales of about $3 billion for 2007, but the company expects sales to fall dramatically in 2008 as generic rivals hit the market.

Although most cases of osteonecrosis of the jaw related to Fosamax side effects have occurred after dental work several cases have been reported to occur without any prior dental work. If you are currently taking Fosamax you may be at risk of developing osteonecrosis. If you have been injured by Fosamax side effects you may be entitled to compensation. For more information about your legal rights contact the Fosamax Attorneys of Ennis & Ennis, P.A. today.


 

 

 

All items marked with * are required
 
* Name:
* Street Address:
* City:
* State:
* Zip Code:
* Email Address:
* Phone Number :
(123-123-1234)
Occupation:
Reason for contacting us:
How did you hear about us?
If you found us on the internet what search engine did you use?
Additional information: